The pathogenesis of amyotrophic lateral sclerosis (ALS) is still not very well understood. A new study on the genetic origin of ALS entitled “Antisense Proline-Arginine RAN Dipeptides Linked to C9ORF72-ALS/FTD Form Toxic Nuclear Aggregates that Initiate In Vitro and In Vivo Neuronal Death” was published in the Journal…

The ALS Association announced that $326,662 will be used to fund new Amyotrophic Lateral Sclerosis (ALS) research. The new funding will seek to expand ongoing research projects to increase the knowledge of the most frequent genetic cause of the disease and support clinical trials dedicated to those that carry…

A new study entitled “Aggregation propensities of Superoxide Dismutase G93 hotspot mutants mirror Amyotrophic Lateral Sclerosis clinical phenotypes” identified a mechanism that leads to the aggregation of SOD protein mutant forms that are typically found in Amyotrophic lateral sclerosis (ALS) motor neurons. The study opens new therapeutic avenues…

New research at Washington University School of Medicine in St. Louis and Cedars-Sinai Medical Center in Los Angeles indicates that genetic mutations may underlie more amyotrophic lateral sclerosis (ALS) than scientists had previously realized. The research results also revealed that the quantity of mutated genes influences at what age…

A new study entitled “Angiotensin-Converting Enzyme Inhibitors and Amyotrophic Lateral Sclerosis Risk A Total Population–Based Case-Control Study” reports that using angiotensin-converting enzyme inhibitors (ACEIs) significantly decreases the risk for developing amyotrophic lateral sclerosis. The study was published in the journal Jama Neurology. Amyotrophic lateral sclerosis (ALS), also…

Early treatment with AL-S Pharma‘s infusion therapy AP-101 significantly extended survival and delayed the need for respiratory support in people with amyotrophic lateral sclerosis (ALS), compared with a six-month delay in starting therapy, new trial data show. The therapy candidate is being developed to target and clear…

The ALS Network and ALS United are inviting U.S. researchers to submit proposals for a new round of funding aimed at accelerating progress toward new treatments for amyotrophic lateral sclerosis (ALS). The funding is part of the expanding ALS Research Innovation Initiative. It’s intended to support “bold” and …

Several commonly used medications may be repurposed to extend survival in people with amyotrophic lateral sclerosis (ALS), according to an analysis of the electronic medical records of more than 11,000 U.S. veterans. Researchers found that certain classes of medications were associated with improved survival in ALS, including statins, which…

An analysis of how polarized light interacts with clumps of proteins in the eyes may help differentiate amyotrophic lateral sclerosis (ALS) from Alzheimer’s disease and related conditions, a new study shows. In experiments using post-mortem retinal samples — a light-sensitive layer at the back of the eye — researchers…

A Phase 2 clinical trial showed that early treatment with the experimental oral therapy PrimeC slowed functional decline and reduced the risk of death or ALS complications for people with amyotrophic lateral sclerosis (ALS) compared with a six-month delay in treatment. Top-line results from the main Phase 2…